Melatonin reverses the decreases in hippocampal protein serine/threonine kinases observed in an animal model of autism

Journal of Pineal Research

Volumn 56, Issue 1, 2014, Pages 1-11

  Tian, Yun ^a   Yabuki, Yasushi ^b   Moriguchi, Shigeki ^b   Fukunaga, Kohji ^b   Mao, Pei Jiang ^a,c   Hong, Ling Juan ^a   Lu, Ying Mei ^d   Wang, Rui ^a,e   Ahmed, Muhammad Masood ^a   Liao, Mei Hua ^a   Huang, Ji Yun ^a   Zhang, Rui Ting ^a   Zhou, Tian Yi ^a   Long, Sen ^a,f   Han, Feng ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b TOHOKU UNIVERSITY   (Japan)

^c Zhejiang Research Institute of Traditional Chinese Medicine   (China)

^d ZHEJIANG UNIVERSITY CITY COLLEGE   (China)

^e NINGXIA MEDICAL UNIVERSITY   (China)

^f Hangzhou No3 People's Hospital   (China)

Author keywords

autism; CaMKII; hippocampus; melatonin; phosphorylation; valproic acid

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CYCLIC AMP DEPENDENT PROTEIN KINASE; MELATONIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; PROTEIN KINASE C; PROTEIN SERINE THREONINE KINASE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; AUTISM; BRAIN SLICE; CELL MEMBRANE POTENTIAL; CONTROLLED STUDY; ELECTRIC POTENTIAL; ENZYME PHOSPHORYLATION; FEMALE; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; LONG TERM POTENTIATION; NONHUMAN; PYRAMIDAL NERVE CELL; RAT; SIGNAL TRANSDUCTION; SOCIAL INTERACTION;

AUTISM; CAMKII; HIPPOCAMPUS; MELATONIN; PHOSPHORYLATION; VALPROIC ACID;

ANALYSIS OF VARIANCE; ANIMALS; ANTIOXIDANTS; AUTISTIC DISORDER; BEHAVIOR, ANIMAL; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; DISEASE MODELS, ANIMAL; FEMALE; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; MELATONIN; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; VALPROIC ACID;

EID: 84890114613     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12081     Document Type: Article

References (62)

1. Cohen D, Pichard N, Tordjman S, et al. Specific genetic disorders and autism: clinical contribution towards their identification. J Autism Dev Disord 2005; 35: 103-116.
2. Feinstein C, Singh S,. Social phenotypes in neurogenetic syndromes. Child Adolesc Psychiatr Clin N Am 2007; 16: 631-647.
3. Moessner R, Marshall CR, Sutcliffe JS, et al. Contribution of SHANK3 mutations to autism spectrum disorder. Am J Hum Genet 2007; 81: 1289-1297.
4. Folstein SE, Rosen-Sheidley B,. Genetics of autism: complex aetiology for a heterogeneous disorder. Nat Rev Genet 2001; 2: 943-955.
5. Edgin JO, Pennington BF,. Spatial cognition in autism spectrum disorders: superior, impaired, or just intact? J Autism Dev Disord 2005; 35: 729-745.
6. Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009; 360: 1597-1605.
7. Takeuchi K, Gertner MJ, Zhou J, et al. Dysregulation of synaptic plasticity precedes appearance of morphological defects in a Pten conditional knockout mouse model of autism. Proc Natl Acad Sci USA 2013; 110: 4738-4743.
8. Fassio A, Patry L, Congia S, et al. SYN1loss-of-function mutations in autism and partial epilepsy cause impaired synaptic function. Hum Mol Genet 2011; 20: 2297-2307.
9. Abel T, Nguyen PV,. Regulation of hippocampus-dependent memory by cyclic APM-dependent protein kinase. Prog Brain Res 2008; 169: 97-115.
10. Colbran RJ, Brown AM,. Calcium/calmodulin-dependent protein kinase II and synaptic plasticity. Curr Opin Neurobiol 2004; 14: 318-327.
11. Elgersma Y, Fedorov NB, Ikonen S, et al. Inhibitory autophosphorylation of CaMKII controls PSD association, plasticity, and learning. Neuron 2002; 36: 493-505.
12. 2+/calmodulin-dependent protein kinase II-discovery, progress in a quarter of a century, and perspective: implication for learning and memory. Biol Pharm Bull 2005; 28: 1342-1354.
13. Birnbaum SG, Yuan PX, Wang M, et al. Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. Science 2004; 306: 882-884.
14. Gambrill AC, Storey GP, Barria A,. Dynamic regulation of NMDA receptor transmission. J Neurophysiol 2011; 105: 162-171.
15. Lau CG, Zukin RS,. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat Rev Neurosci 2007; 8: 413-426.
16. Bromley RL, Mawer G, Clayton-Smith J, et al. Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology 2008; 71: 1923-1924.
17. Vinten J, Adab N, Kini U,. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 2005; 64: 949-954.
18. Burket JA, Herndon AL, Winebarger EE, et al. Complex effects of mGluR5 antagonism on sociability and stereotypic behaviors in mice:possible implications for the pharmacotherapy of autism spectrum disorders. Brain Res Bull 2011; 86: 152-158.
19. Melke J, Goubran Botros H, Chaste P, et al. Abnormal melatonin synthesis in autism spectrum disorders. Mol Psychiatry 2008; 13: 90-98.
20. Stehle JH, Saade A, Rawashdeh O, et al. A survey of molecular details in the human pineal gland in the light of phylogeny, structure, function and chronobiological diseases. J Pineal Res 2011; 51: 17-43.
21. Cardinali DP, Srinivasan V, Brzezinski A, et al. Melatonin and its analogs in insomnia and depression. J Pineal Res 2012; 52: 365-375.
22. Rossignol DA,. Novel and emerging treatments for autism spectrum disorders: a systematic review. Ann Clin Psychiatry 2009; 21: 213-236.
23. Doyen C, Mighiu D, Kaye K, et al. Melatonin in children with autistic spectrum disorders: recent and practical data. Eur Child Adolesc Psychiatry 2011; 20: 231-239.
24. Corrales A, Martínez P, García S,. Long-term oral administration of melatonin improves spatial learning and memory and protects against cholinergic degeneration in middle-aged Ts65Dn mice, a model of Down syndrome. J Pineal Res 2013; 54: 346-358.
25. Wang X, Wang ZH, Wu YY, et al. Melatonin attenuates scopolamine-induced memory/synaptic disorder by rescuing EPACs/miR-124/Egr1 pathway. Mol Neurobiol 2013; 47: 373-381.
26. Furio AM, Brusco LI, Cardinali DP,. Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study. J Pineal Res 2007; 43: 404-409.
27. Jean-Louis G, von Gizycki H, Zizi F,. Melatonin effects on sleep, mood, and cognition in elderly with mild cognitive impairment. J Pineal Res 1998; 25: 177-183.
28. Shioda N, Yamamoto Y, Han F, et al. A novel cognitive enhancer, ZSET1446/ST101, promotes hippocampal neurogenesis and ameliorates depressive behavior in olfactory bulbectomized mice. J Pharmacol Exp Ther 2010; 333: 43-50.
29. Schneider T, Przewłocki R,. Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology 2005; 30: 80-89.
30. Han F, Shioda N, Moriguchi S, et al. ZSET1446 (ST101) treatment rescues olfactory bulbectomy-induced memory impairment by activating CaM kinase II and protein kinase C in mouse hippocampus. J Pharmacol Exp Ther 2008; 32: 127-134.
31. Peça J, Feliciano C, Ting JT, et al. Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 2011; 472: 437-442.
32. Han F, Chen YX, Lu YM, et al. Regulation of the ischemia-induced autophagy-lysosome processes by nitrosative stress in endothelial cells. J Pineal Res 2011; 51: 124-135.
33. Han F, Tao RR, Zhang GS, et al. Melatonin ameliorates ischemic-like injury-evoked nitrosative stress: involvement of HtrA2/PED pathways in endothelial cells. J Pineal Res 2011; 50: 281-291.
34. 2+/calmodulin- dependent protein kinase II and protein kinase C activities mediate extracellular glucose-regulated hippocampal synaptic efficacy. Mol Cell Neurosci 2011; 46: 101-107.
35. Fukunaga K, Miyamoto E,. A working model of CaM kinase II activity in hippocampal long-term potentiation and memory. Neurosci Res 2000; 38: 3-17.
36. Han F, Shirasaki Y, Fukunaga K,. Microsphere embolism-induced endothelial nitric oxide synthase expression mediates disruption of the blood brain barrier in rat brain. J Neurochem 2006; 99: 97-106.
37. Li X, Han F, Liu D, et al. Changes of Bax, Bcl-2 and apoptosis in hippocampus in the rat model of post-traumatic stress disorder. Neurol Res 2010; 32: 579-586.
38. Hayashi Y, Shi SH, Esteban JA, et al. Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction. Science 2000; 287: 2262-2267.
39. Håkansson K, Galdi S, Hendrick J, et al. Regulation of phosphorylation of the GluR1 AMPA receptor by dopamine D2 receptors. J Neurochem 2006; 96: 482-488.
40. Silverman JL, Tolu SS, Barkan CL, et al. Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP. Neuropsychopharmacology 2010; 35: 976-989.
41. Moriguchi S, Han F, Nakagawasai O, et al. Decreased calcium/calmodulin- dependent protein kinase II and protein kinase C activities mediate impairment of the hippocampal long term potentiation in the olfactory bulbectomized mice. J Neurochem 2006; 97: 22-29.
42. Bingol B, Wang CF, Arnott D, et al. Autophosphorylated CaM KII alpha acts as a scaffold to recruit proteosome to dendritic spines. Cell 2010; 140: 567-578.
43. Zhang MM, Yu K, Xiao C, et al. The influence of developmental periods of sodium valproate exposure on synaptic plasticity in CA1 region of rat hippocampus. Neurosci Lett 2003; 351: 165-168.
44. Zhang MM, Xiao C, Yu K, et al. Effects of sodium valproate on synaptic plasticity in the CA1 region of rat hippocampus. Food Chem Toxicol 2003; 41: 1617-1623.
45. Wu P, Jiang L, Chen H,. Sodium valproate at the therapeutic concentration inhibits the induction but not the maintenance phase of long-term potentiation in rat hippocampal CA1 area. Biochem Biophys Res Commun 2010; 391: 582-586.
46. Roullet FI, Wollaston L, Decatanzaro D, et al. Behavioral and molecular changes in the mouse in response to prenatal exposure to the anti-epileptic drug valproic acid. Neuroscience 2010; 170: 514-522.
47. Tordjman S, Anderson GM, Pichard N, et al. Nocturnal excretion of 6-sulphatoxymelatonin in children and adolescents with autistic disorder. Biol Psychiatry 2005; 57: 134-138.
48. Chamberlain RS, Herman BH,. A novel biochemical model linking dysfunctions in brain melatonin, proopiomel anocortin peptides, and serotonin autism. Biol Psychiatry 1990; 28: 773-793.
49. Shattock P, Whiteley P,. Biochemical aspects in autism spectrum disorders: updating the opioid-excess theory and presenting new opportunities for biomedical intervention. Expert Opin Ther Targets 2002; 6: 175-183.
50. Gorfine T, Zisapel N,. Melatonin and the human hippocampus, a time dependent interplay. J Pineal Res 2007; 43: 80-86.
51. Yoo DY, Kim W, Lee CH, et al. Melatonin improves D-galactose-induced aging effects on behavior, neurogenesis, and lipid peroxidation in the mouse dentate gyrus via increasing pCREB expression. J Pineal Res 2012; 52: 21-28.
52. Braam W, Didden R, Maas AP, et al. Melatonin decreases daytime challenging behaviour in persons with intellectual disability and chronic insomnia. J Intellect Disabil Res 2010; 54: 52-59.
53. Chaudhury D, Wang LM, Colwell CS,. Circadian regulation of hippocampal long-term potentiation. J Biol Rhythms 2005; 20: 225-236.
54. Bourgeron T,. A synaptic trek to autism. Curr Opin Neurobiol 2009; 19: 231-234.
55. Olcese JM, Cao C, Mori T, et al. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J Pineal Res 2009; 47: 82-96.
56. Baydas G, Yasar A, Tuzcu M,. Comparison of the impact of melatonin on chronic ethanol-induced learning and memory impairment between young and aged rats. J Pineal Res 2005; 39: 346-352.
57. Lee GY, Brown LM, Teyler TJ,. The effects of anticonvulsant drugs on long-term potentiation (LTP) in the rat hippocampus. Brain Res Bull 1996; 39: 39-42.
58. Ebert DH, Greenberg ME,. Activity-dependent neuronal signalling and autism spectrum disorder. Nature 2013; 493: 327-337.
59. Lisman J, Schulman H, Cline H,. The molecular basis of CaMKII function in synaptic and behavioural memory. Nat Rev Neurosci 2002; 3: 175-190.
60. Zhao WJ, Zhang M, Miao Y, et al. Melatonin potentiates glycine currents through a PLC/PKC signalling pathway in rat retinal ganglion cells. J Physiol 2010; 588 (Pt 14): 2605-2619.
61. Larson J, Jessen RE, Uz T, et al. Impaired hippocampal long term-potentiation in melatonin MT2 receptor-deficient mice. Neurosci Lett 2006; 393: 23-26.
62. Chaste P, Clement N, Mercati O, et al. Identification of pathway-biased and deleterious melatonin receptor mutants in autism spectrum disorders and in the general population. PLoS ONE 2010; 5: e11495.